A person walks past the Pfizer Headquarters building in the Manhattan borough of New York City, New York, U.S., November 9, 2020.
Pfizer said it would instead focus on a once-daily, modified release version of danuglipron and "gathering the data to understand its potential profile".
In the current study of the twice-daily version, Pfizer said the drug, however, met the main goal of reducing weight in adults with obesity and without type 2 diabetes.
Pfizer said while the common side effects in the twice-daily version study were mild, it saw high rates of those events in the trial.
However, no new safety signals were observed in the study, Pfizer said.
Persons:
Carlo Allegri, danuglipron, Eli Lilly's, Mikael Dolsten, Pfizer, Manas Mishra, Michael Erman, Shinjini
Organizations:
Pfizer, REUTERS, Zepbound, Thomson
Locations:
Manhattan, New York City , New York, U.S, Bengaluru, New York